Initiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational Study

Original Data

Rev Diabet Stud, 2008, 5(3):154-162

DOI 10.1900/RDS.2008.5.154

Initiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational Study

Leif Breum¹, Thomas Almdal²^,³, Pia Eiken⁴, Per Lund⁵, Erik Christiansen⁶, on behalf of the Danish BIAsp Study Group

¹Department of Medicine, Koge Hospital, Koge, Denmark
²Department of Endocrinology, Hvidovre University Hospital, Copenhagen, Denmark
³Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
⁴Department of Cardiology and Endocrinology, Hillerod Hospital, Hillerod, Denmark
⁵Department of Medicine, Helsingor Hospital, Helsingor, Denmark
⁶Novo Nordisk Scandinavia AB, Copenhagen, Denmark
Address correspondence to: Leif Breum, e-mail: lbru@regionsjaelland.dk

Manuscript submitted August 22, 2008; resubmitted November 11, 2008; accepted November 16, 2008.

Keywords: type 2 diabetes, human insulin, glycemic control, biphasic insulin aspart, BIAsp, HbA1c

Abstract

OBJECTIVE: To investigate tolerability and glycemic control over 26 weeks in patients with type 2 diabetes (T2D) who initiated insulin with, or switched to, biphasic insulin aspart 30/70 (BIAsp 30) in routine clinical care. METHODS: This was a non-randomized, non-interventional, open-label, observational study involving patients under the care of approximately 150 insulin-prescribing physicians in Denmark. All patients enrolled were prescribed BIAsp 30 in routine care. Starting dose, dose titration and injection frequency were determined individually by each physician. Information on serious adverse drug reactions (SADR), glycemic parameters and hypoglycemic events were obtained from patients’ notes, patients’ diaries and recall, and transferred to case report forms by physicians at baseline (during 4 weeks prior to BIAsp 30 therapy) and after 12 and 26 weeks of treatment. RESULTS: 421 subjects were recruited and 392 provided safety data. The age (mean ± SD) was 62.0 ± 11.4 years, body mass index (BMI) 30.4 ± 6.4 kg/m², duration of diabetes 9.1 ± 8.1 years and HbA1c (%) 9.4 ± 1.7. 199 subjects were prior insulin users and 193 were insulin-naïve patients. Four patients reported a SADR (3 hypoglycemia, 1 severe hypoglycemia). HbA1c was significantly reduced after 26 weeks of BIAsp 30 therapy: prior insulin users -1.2%, insulin-naïve patients -2.2% (both p < 0.001). 28% and 41% of patients, respectively, reached target HbA1c < 7%. Overall the hypoglycemia rate was lower for insulin-naïve patients than for prior insulin users: 5.0 vs. 6.6 episodes/patient-year (p < 0.05). CONCLUSION: Initiating insulin with, or switching insulin to, BIAsp 30 in routine care was safe and effective in patients with T2D.

Fulltext: HTML , PDF (427KB)

This article has been cited by other articles:

	Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting Palmer JL, Knudsen MS, Aagren M, Thomsen TL J Med Econ 2010. 13(2):212-220

	Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes Valensi P Diabetes Metab Syndr Obes Targets Ther 2009. 2:61-71